TY - JOUR
T1 - Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort
AU - BELNEU Consortium
AU - EU EOD Consortium
AU - Verheijen, Jan
AU - van der Zee, Julie
AU - Gijselinck, Ilse
AU - Van den Bossche, Tobi
AU - Dillen, Lubina
AU - Heeman, Bavo
AU - Gómez-Tortosa, Estrella
AU - Lladó, Albert
AU - Sanchez-Valle, Raquel
AU - Graff, Caroline
AU - Pastor, Pau
AU - Pastor, Maria A.
AU - Benussi, Luisa
AU - Ghidoni, Roberta
AU - Binetti, Giuliano
AU - Clarimon, Jordi
AU - de Mendonça, Alexandre
AU - Gelpi, Ellen
AU - Tsolaki, Magda
AU - Diehl-Schmid, Janine
AU - Nacmias, Benedetta
AU - Almeida, Maria Rosário
AU - Borroni, Barbara
AU - Matej, Radoslav
AU - Ruiz, Agustín
AU - Engelborghs, Sebastiaan
AU - Vandenberghe, Rik
AU - De Deyn, Peter P.
AU - Cruts, Marc
AU - Van Broeckhoven, Christine
AU - Sleegers, Kristel
AU - Goeman, Johan
AU - Nuytten, Dirk
AU - Vandenbulcke, Mathieu
AU - Santens, Patrick
AU - De Bleecker, Jan
AU - Sieben, Anne
AU - Dermaut, Bart
AU - Versijpt, Jan
AU - Michotte, Alex
AU - Deryck, Olivier
AU - Bergmans, Bruno
AU - Willems, Christiana
AU - Ivanoiu, Adrian
AU - Salmon, Eric
AU - Alexopoulos, Panagiotis
AU - Sorbi, Sandro
AU - Bessi, Valentina
AU - Bagnoli, Silvia
AU - Couto, Frederico Simões do
N1 - Funding Information:
SE received research funding from Janssen Pharmaceutica and from ADx Neurosciences and was/is consultant for Innogenetics/Fujirebio Europe, Lundbeck, Pfizer, Novartis, UCB, Roche diagnostics, Nutricia/Danone, Lilly, and Biogen. Other co-authors declare that they have no conflict of interest.
Funding Information:
At the Antwerp site, the data generation was in part funded by the Belgium Science Policy Office Interuniversity Attraction Poles program ( http://www.belspo.be ), the Alzheimer Research Foundation (S#13023) ( http://alzh.org ), the Flemish Government Initiated Methusalem Excellence Program to CVB, the Research Foundation Flanders (G043211N) (FWO, http://www.fwo.be ), the University Research Fund, the Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research, the MetLife Foundation Research Award to CVB, the EU FP7 project AgedBrainSYSBIO under grant agreement no. 305299 ( http://ec.europa.eu/research/fp7 ). The Brescia IRCCS Fatebenefratelli site was funded by Ricerca Corrente, Italian Ministry of Health. EGT is supported by grants SAF2010-18277, PI14/00099, and FEDER funds (Madrid, Spain). The Florence site is funded by Fondazione Cassa di Risparmio di Pistoia e Pescia (grant 2014.0365 to BN), and a grant from Ministry of Health no. RF-2010-2319722 to SS. The Prague site was partly supported by research programs PRVOUK-P26/LF1/4 and P27/LF1/1 and OPPK CZ.2.16/3.1.00/24509 (Charles University, Prague, Czech Republic). AL receives a grant (PI14/00282) from the Spanish Ministry of Economy and Competitiveness ISCIII and co-funded by the European Regional Development Fund (ERDF). The Stockholm site (CG) was financially supported by Swedish Brain Power, Swedish Research Council (grant numbers 521-2010-3134; 2015-02926), Gun and Bertil Stohne, Gamla tjänarinnor, Demensfonden, Sweden Alzheimer Foundation, King Gustaf V, and Queen Victoria's Foundation of Freemasons and StratNeuro at Karolinska Institute (KI), Swedish Brain Foundation.
Publisher Copyright:
© 2017 The Author(s)
PY - 2018/2
Y1 - 2018/2
N2 - TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course. We performed targeted resequencing of TBK1 in 1253 early onset Alzheimer's disease (EOAD) patients from 8 European countries to investigate whether pathogenic TBK1 mutations are enriched among patients with clinical diagnosis of EOAD. Variant frequencies were compared against 2117 origin-matched controls. We identified only 1 LoF mutation (p.Thr79del) in a patient clinically diagnosed with Alzheimer's disease and a positive family history of ALS. We did not observe enrichment of rare variants in EOAD patients compared to controls, nor of rare variants affecting NFκB induction. Of 3 common coding variants, rs7486100 showed evidence of association (OR 1.46 [95% CI 1.13–1.9]; p-value 0.01). Homozygous carriers of the risk allele showed reduced expression of TBK1 (p-value 0.03). Our findings are not indicative of a significant role for TBK1 mutations in EOAD. The association between common variants in TBK1, disease risk and reduced TBK1 expression warrants follow-up in FTD/ALS cohorts.
AB - TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course. We performed targeted resequencing of TBK1 in 1253 early onset Alzheimer's disease (EOAD) patients from 8 European countries to investigate whether pathogenic TBK1 mutations are enriched among patients with clinical diagnosis of EOAD. Variant frequencies were compared against 2117 origin-matched controls. We identified only 1 LoF mutation (p.Thr79del) in a patient clinically diagnosed with Alzheimer's disease and a positive family history of ALS. We did not observe enrichment of rare variants in EOAD patients compared to controls, nor of rare variants affecting NFκB induction. Of 3 common coding variants, rs7486100 showed evidence of association (OR 1.46 [95% CI 1.13–1.9]; p-value 0.01). Homozygous carriers of the risk allele showed reduced expression of TBK1 (p-value 0.03). Our findings are not indicative of a significant role for TBK1 mutations in EOAD. The association between common variants in TBK1, disease risk and reduced TBK1 expression warrants follow-up in FTD/ALS cohorts.
KW - Early onset Alzheimer's disease
KW - Frontotemporal dementia
KW - Loss-of-function
KW - RNA sequencing
KW - TBK1
UR - http://www.scopus.com/inward/record.url?scp=85035129689&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2017.10.012
DO - 10.1016/j.neurobiolaging.2017.10.012
M3 - Article
C2 - 29146049
AN - SCOPUS:85035129689
SN - 0197-4580
VL - 62
SP - 245.e1-245.e7
JO - Neurobiology of Aging
JF - Neurobiology of Aging
ER -